Exit, what exit? VCs commit to half of Durata's devalued $67.5m IPO
This article was originally published in Scrip
Executive Summary
The floodgates haven't exactly opened, but Durata Therapeutics' $67.5 million initial public offering on 19 July followed multiple IPO filings this month by biotechnology companies that hope to leverage the public markets to support drug development and commercialization.